Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. reported a first-quarter 2026 net loss of $130.5M, an improvement from $221.7M a year earlier, driven by sharply lower research and development and general and administrative spending. Total operating expenses fell to $130.4M from $221.6M, reflecting portfolio and cost-optimization efforts.
Cash and cash equivalents were $273.1M and marketable securities were $74.7M as of March 31, 2026, supporting management’s view that existing liquidity should fund operations for at least one year after the statements’ issuance. Net cash used in operating activities was $149.9M for the quarter.
To bolster its balance sheet, Biohaven issued 17,164,940 common shares under its at-the-market equity program, generating net proceeds of $178.9M and increasing outstanding shares to 150,506,490. Notes payable tied to a revenue-sharing Note Purchase Agreement had a fair value of $241.9M, highlighting a significant non-traditional financing obligation linked to future sales and regulatory milestones. The company continues to focus on three key late-stage programs in Kv7 ion channel modulation, MoDE/TRAP extracellular protein degraders, and myostatin-activin pathway targeting for neuromuscular and metabolic diseases.
Biohaven Ltd. reported first quarter 2026 results showing a smaller loss and stronger balance sheet while advancing multiple late-stage drug programs. Net loss narrowed to $130.5 million, or $0.88 per share, compared with $221.7 million, or $2.17 per share, a year earlier.
R&D expenses fell to $103.8 million from $187.6 million, mainly from program reprioritization and lower preclinical and share-based compensation costs. Cash, cash equivalents, marketable securities and restricted cash totaled $351.8 million as of March 31, 2026, supporting a broad pipeline across epilepsy, obesity, immunology, oncology and Parkinson’s disease.
The company expects pivotal epilepsy data for opakalim and Phase 2 obesity data for taldefgrobep alfa in the second half of 2026, and plans to start pivotal trials for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy by mid-2026. Non-GAAP adjusted net loss improved to $102.2 million, or $0.69 per share, as Biohaven continues disciplined cost management while progressing its clinical programs.
Biohaven Ltd. reported the results of its 2026 annual meeting of shareholders. Shareholders elected Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin as directors for terms expiring at the 2029 annual meeting, each receiving over 76 million votes in favor and more than 14 million votes against, with additional abstentions and 32,137,064 broker non-votes.
Shareholders also approved the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, with 123,723,636 votes for, 214,123 against, and 1,410,634 abstentions. In addition, they approved the non-binding advisory vote on compensation for the company’s named executive officers, with 87,521,620 votes for, 4,202,883 against, 1,486,826 abstentions, and 32,137,064 broker non-votes.
Biohaven Ltd. director Kishan Mehta received a grant of 68,693 stock options on April 28, 2026. Each option gives the right to buy one common share at an exercise price of $9.61 and expires on April 28, 2036.
According to the vesting terms, all 68,693 options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided Mehta continues to serve with the company through that vesting date.
Biohaven Ltd. director Gregory Bailey reported receiving a grant of stock options as part of his compensation. The award covers 68,693 stock options, each allowing him to buy one common share at an exercise price of $9.61 per share.
The options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company until that vesting date. After this grant, he holds 68,693 options directly, and this filing does not show any open-market buying or selling of shares.
Biohaven Ltd. director Michael Thomas Heffernan received a grant of stock options on April 28, 2026. The award covers 68,693 options, each allowing him to buy one common share at an exercise price of $9.61. After this grant, he holds 68,693 options directly.
These options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company through that date. The options expire on April 28, 2036. This is a compensation-related grant rather than an open-market share purchase or sale.
Biohaven Ltd. director Irina Antonijevic received a grant of stock options covering 68,693 common shares, with an exercise price of 9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to her continuous service, and expire on April 28, 2036.
Biohaven Ltd. director John W. Childs reported a grant of stock options covering 68,693 Common Shares. The options have an exercise price of $9.61 per share, expire on April 28, 2036, and were received as a compensation award rather than an open‑market purchase.
These options will vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, provided Childs continues serving the company through that date. Following this grant, he holds 68,693 stock options directly.
Biohaven Ltd. director Robert J. Hugin received a grant of stock options, giving him the right to buy 68,693 common shares at an exercise price of $9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to his continuous service. After this award, he holds 68,693 stock options directly, with an expiration date of April 28, 2036.
Biohaven Ltd. director Julia P. Gregory received a grant of 68,693 stock options to buy Common Shares at an exercise price of $9.61 per share. The options expire on April 28, 2036 and represent compensation rather than an open-market purchase.
These options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided she continues serving the company through that vesting date. After this award, she holds 68,693 stock options directly.